A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
A Pivotal Registrational Phase 3 Study of Olverembatinib Combined With Chemotherapy Versus Investigator's Choice of TKI Combined With Chemotherapy in Patients With Newly Diagnosed Ph+ ALL
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Expanded Access
Expanded Access
Available
- Available: Expanded access is currently available for this investigational treatment, and patients who are not participants in the clinical study may be able to gain access to the drug, biologic, or medical device being studied.
- No longer available: Expanded access was available for this intervention previously but is not currently available and will not be available in the future.
- Temporarily not available: Expanded access is not currently available for this intervention but is expected to be available in the future.
- Approved for marketing: The intervention has been approved by the U.S. Food and Drug Administration for use by the public.
Contacts and Locations
Study Contact
Study Contact
- Name: Ascentage Clinical Operations
- Phone Number: 301-291-5658
- Email: clinical-trials@ascentage.com
Study Locations
-
-
New South Wales
-
St Leonards, New South Wales, Australia
- Active, not recruiting
- Royal North Shore Hospital
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Active, not recruiting
- Royal Adelaide Hospital
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Active, not recruiting
- Alfred Health
-
-
Washington
-
Perth, Washington, Australia, 6000
- Active, not recruiting
- Royal Perth Hospital
-
-
-
-
Anhui
-
Bengbu, Anhui, China, 233000
- Not yet recruiting
- The First Affiliated Hospital of Bengbu Medical School
-
Contact:
- Yanli Yang, M.D.
-
Principal Investigator:
- Yanli Yang, M.D.
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 214426
- Recruiting
- Xinqiao Hospital of Army Medical University
-
Contact:
- Cheng Zhang, M.D.
-
Principal Investigator:
- Cheng Zhang, M.D.
-
-
Guangzhou
-
Guangdong, Guangzhou, China, 510080
- Recruiting
- Guangdong Province People's Hospital
-
Contact:
- Jianyu Weng, M.D.
-
Principal Investigator:
- Jianyu Weng, M.D.
-
Guangdong, Guangzhou, China, 510515
- Recruiting
- Nanfang Hospital of Southern Medical University
-
Contact:
- Hongsheng Zhou, M.D.
-
Principal Investigator:
- Hongsheng Zhou, M.D.
-
-
Henan
-
Zhengzhou, Henan, China, 450003
- Recruiting
- Henan Cancer Hospital
-
Contact:
- Xudong Wei, M.D.
-
Principal Investigator:
- Xudong Wei, M.D.
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Recruiting
- Wuhan Union Hospital of Tongji Medical College of Huazhong University of Science and Technology
-
Contact:
- Mei Hong, M.D.
-
Principal Investigator:
- Mei Hong, M.D.
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215006
- Recruiting
- The First Affiliated Hospital of Suzhou University
-
Contact:
- Suning Chen, M.D.,Ph.D.
-
Principal Investigator:
- Suning Chen, M.D.,Ph.D.
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200025
- Not yet recruiting
- Shanghai Jiao Tong University School of Medicine Ruijin Hospital
-
Contact:
- Weili Zhao, M.D.,Ph.D.
-
Principal Investigator:
- Weili Zhao, M.D.,Ph.D.
-
-
Sichuan
-
Chengdu, Sichuan, China, 610044
- Recruiting
- West China Hospital of Sichuan University
-
Contact:
- Yu Wu, M.D.
-
Principal Investigator:
- Yu Wu, M.D.
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 215127
- Recruiting
- Institute of Blood Transfusion of Chinese Academy of Medical Sciences
-
Contact:
- Ying Wang, M.D.
-
Principal Investigator:
- Ying Wang, M.D.
-
-
-
-
-
Brno, Czechia, 62500
- Not yet recruiting
- Ascentage Investigative Site #8647
-
Hradec Králové, Czechia, 50005
- Not yet recruiting
- Ascentage Investigative Site #6305
-
Ostrava, Czechia, 70852
- Not yet recruiting
- Ascentage Investigative Site #6304
-
Prague, Czechia, 10034
- Not yet recruiting
- Ascentage Investigative Site #6302
-
Prague, Czechia, 12800
- Not yet recruiting
- Ascentage Investigative Site #6309
-
-
-
-
-
Le Chesnay, France, 78150
- Not yet recruiting
- Ascentage Investigative Site #5020
-
Lyon, France, 69008
- Not yet recruiting
- Ascentage Investigative Site #5021
-
Nantes, France, 44000
- Not yet recruiting
- Ascentage Investigative Site #5013
-
Nice, France, 06200
- Not yet recruiting
- Ascentage Investigative Site #5025
-
Pessac, France, 33604
- Not yet recruiting
- Ascentage Investigative Site #5019
-
Pierre-Bénite, France, 69495
- Not yet recruiting
- Ascentage Investigative Site #5024
-
Poitiers, France, 86021
- Not yet recruiting
- Ascentage Investigative Site #5022
-
Toulouse, France, 31059
- Not yet recruiting
- Ascentage Investigative Site #5018
-
-
-
-
-
Bologna, Italy, 40138
- Not yet recruiting
- Ascentage Investigative Site #5538
-
Meldola, Italy, 47014
- Not yet recruiting
- Ascentage Investigative Site #5529
-
Milan, Italy, 20132
- Not yet recruiting
- Ascentage Investigative Site #5539
-
Monza, Italy, 20900
- Not yet recruiting
- Ascentage Investigative Site #5533
-
Ravenna, Italy, 48121
- Not yet recruiting
- Ascentage Investigative Site #5540
-
Roma, Italy, 00138
- Not yet recruiting
- Ascentage Investigative Site #5531
-
Torino, Italy, 10126
- Not yet recruiting
- Ascentage Investigative Site #5550
-
Varese, Italy, 21100
- Not yet recruiting
- Ascentage Investigative Site #5536
-
-
-
-
-
Bucharest, Romania, 020125
- Not yet recruiting
- Ascentage Investigative Site #6503
-
Cluj-Napoca, Romania, 400015
- Not yet recruiting
- Ascentage Investigative Site #6502
-
Craiova, Romania, 200143
- Not yet recruiting
- Ascentage Investigative Site #6507
-
Iași, Romania, 700483
- Not yet recruiting
- Ascentage Investigative Site #6504
-
-
-
-
-
Singapore, Singapore, 119074
- Not yet recruiting
- Ascentage Investigative Site #6602
-
Singapore, Singapore, 169608
- Not yet recruiting
- Ascentage Investigative Site #6603
-
Singapore, Singapore, 308433
- Not yet recruiting
- Ascentage Investigative Site #6604
-
-
-
-
-
Busan, South Korea, 49201
- Not yet recruiting
- Ascentage Investigative Site #8206
-
Busan, South Korea, 49241
- Not yet recruiting
- Ascentage Investigative Site #8207
-
Seoul, South Korea, 03080
- Not yet recruiting
- Ascentage Investigative Site #8201
-
Seoul, South Korea, 05505
- Not yet recruiting
- Ascentage Investigative Site #8202
-
Seoul, South Korea, 06591
- Not yet recruiting
- Ascentage Investigative Site #8203
-
Uijeongbu-si, South Korea, 11759
- Not yet recruiting
- Ascentage Investigative Site #8208
-
-
-
-
-
Badalona, Spain, 08916
- Not yet recruiting
- Ascentage Investigative Site #6018
-
Badalona, Spain, 08916
- Not yet recruiting
- Ascentage Investigative Site #6019
-
Barcelona, Spain, 08035
- Not yet recruiting
- Ascentage Investigative Site #6020
-
Cáceres, Spain, 10003
- Not yet recruiting
- Ascentage Investigative Site #6048
-
Madrid, Spain, 20834
- Not yet recruiting
- Ascentage Investigative Site #6016
-
Madrid, Spain, 20840
- Not yet recruiting
- Ascentage Investigative Site #6049
-
Madrid, Spain, 28006
- Not yet recruiting
- Ascentage Investigative Site #6035
-
Madrid, Spain, 28007
- Not yet recruiting
- Ascentage Investigative Site #6013
-
Madrid, Spain, 28041
- Not yet recruiting
- Ascentage Investigative Site #6011
-
Santander, Spain, 39008
- Not yet recruiting
- Ascentage Investigative Site #6021
-
Seville, Spain, 41010
- Not yet recruiting
- Ascentage Investigative Site #6050
-
Valencia, Spain, 6017
- Not yet recruiting
- Ascentage Investigative Site #6017
-
-
-
-
-
Ankara, Turkey (Türkiye), 06100
- Not yet recruiting
- Ascentage Investigative Site #9201
-
Ankara, Turkey (Türkiye), 06170
- Not yet recruiting
- Ascentage Investigative Site #9204
-
Ankara, Turkey (Türkiye), 06200
- Not yet recruiting
- Ascentage Investigative Site #9212
-
Ankara, Turkey (Türkiye), 06560
- Not yet recruiting
- Ascentage Investigative Site #9209
-
Antalya, Turkey (Türkiye), 07025
- Not yet recruiting
- Ascentage Investigative Site #9205
-
Istanbul, Turkey (Türkiye), 34381
- Not yet recruiting
- Ascentage Investigative Site #9203
-
Izmir, Turkey (Türkiye), 35100
- Not yet recruiting
- Ascentage Investigative Site #9202
-
Kayseri, Turkey (Türkiye), 38039
- Not yet recruiting
- Ascentage Investigative Site #9211
-
Mersin, Turkey (Türkiye), 33200
- Not yet recruiting
- Ascentage Investigative Site #9208
-
Samsun, Turkey (Türkiye), 55139
- Not yet recruiting
- Ascentage Investigative Site #9220
-
Tekirdağ, Turkey (Türkiye), 59030
- Not yet recruiting
- Ascentage Investigative Site #9210
-
-
-
-
-
Birmingham, United Kingdom, B15 2GW
- Not yet recruiting
- Ascentage Investigative Site #7002
-
Glasgow, United Kingdom, G12 0YN
- Not yet recruiting
- Ascentage Investigative Site #7034
-
London, United Kingdom, SW3 6JJ
- Not yet recruiting
- Ascentage Investigative Site #7019
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Not yet recruiting
- Ascentage Investigative Site #1044
-
-
California
-
Duarte, California, United States, 91010
- Not yet recruiting
- Ascentage Investigative Site #1062
-
Los Angeles, California, United States, 90048
- Not yet recruiting
- Ascentage Investigative Site #1134
-
Los Angeles, California, United States, 90095
- Not yet recruiting
- Ascentage Investigative Site #1059
-
-
Florida
-
Miami, Florida, United States, 33155
- Not yet recruiting
- Ascentage Investigative Site #1142
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Not yet recruiting
- Ascentage Investigative Site #1045
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Not yet recruiting
- Ascentage Investigative Site #1158
-
Indianapolis, Indiana, United States, 46237
- Not yet recruiting
- Ascentage Investigative Site #1069
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- Not yet recruiting
- Ascentage Investigative Site #1084
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Not yet recruiting
- Ascentage Investigative Site #1064
-
New Brunswick, New Jersey, United States, 08901
- Not yet recruiting
- Ascentage Investigative Site #1098
-
-
New York
-
Stony Brook, New York, United States, 11794
- Not yet recruiting
- Ascentage Investigative Site #1160
-
The Bronx, New York, United States, 10461
- Not yet recruiting
- Ascentage Investigative Site #1151
-
-
Texas
-
Houston, Texas, United States, 77030
- Not yet recruiting
- Ascentage Investigative Site #1501
-
-
Washington
-
Seattle, Washington, United States, 98104
- Not yet recruiting
- Ascentage Investigative Site #1806
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26506
- Not yet recruiting
- Ascentage Investigative Site #1155
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Newly diagnosed Philadelphia chromosome-positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
- Expected survival of at least 3 months
- ECOG ≤ 2
- Adequate organ function
Exclusion Criteria:
- A history of chronic myeloid leukemia (CML)
- Clinical manifestations of central nervous system (CNS) leukemia or ALL extramedullary infiltration, except lymphadenopathy or hepatosplenomegaly
- Previous or current clinical CNS diseases
- Autoimmune diseases that may involve the CNS
- Use of therapeutic doses of anticoagulants and/or antiplatelet agents; low doses of anticoagulants or antiplatelet agents are allowed
- Use a therapeutic drug that has drug interaction with the investigational drug due to other diseases within 7 days or within 5 half-lives (whichever is shorter) prior to the first receipt of the investigational drug
- Uncontrolled heart diseases
- Any venous thromboembolism in the 6 months prior to randomization, including but not limited to deep vein thrombosis (DVT) or pulmonary embolism
- Use of prohibited drugs
- Disease or medical condition that is unstable or may affect its safety or compliance with the study
- Use of medications known to cause prolonged QT interval
- Active infections requiring systemic treatment
- Disease that severely affects the oral administration and absorption of drugs, or an active gastrointestinal ulcer
- Contraindications to the use of glucocorticoids
- Bleeding disorders unrelated to ALL
- Plan to undergo major surgery
- Allergy to drug ingredients, excipients, or their analogues in the study
- Female subjects who are pregnant or breastfeeding or expect to become pregnant during the study period
- Other malignant tumors within 2 years
- Any symptom or illness that may interfere with the evaluation of the efficacy and safety of the investigational drug, or any other condition or condition that is not appropriate for participation in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Olverembatinib
Olverembatinib in combination with chemotherapy
|
Oral (PO) once every other day (QOD).
|
|
Active Comparator: Investigator's choice of TKI
Investigator's choice of TKI in combination with chemotherapy
|
Oral (PO) once daily (QD).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Minimal Residual Disease Negative CR Rate
Time Frame: Cycle 1 to Cycle 3 (each cycle is 28 days)
|
The minimal residual disease negative CR rate of olverembatinib combined with chemotherapy versus investigator's choice of TKI combined with chemotherapy in subjects with newly diagnosed Ph+ALL.
|
Cycle 1 to Cycle 3 (each cycle is 28 days)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Plasma concentrations of olverembatinib
Time Frame: Cycle 1 to Cycle 3 (each cycle is 28 days)
|
Blood samples will be collected to measure the plasma concentration of olverembatinib.
|
Cycle 1 to Cycle 3 (each cycle is 28 days)
|
|
Event-free Survival (EFS)
Time Frame: Baseline up to 3 to 6 years
|
EFS is defined as the time from study randomization to the date of treatment failure (ITF), relapse from CR, or death from any cause, whichever comes first.
|
Baseline up to 3 to 6 years
|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.
Time Frame: Through study completion (approximately 2 years)
|
According to CTCAE v5.0, the number and frequency of adverse events of test drug will be assessed.
|
Through study completion (approximately 2 years)
|
|
FACT-Leu (Functional Assessment of Cancer Therapy - Leukemia) Score
Time Frame: Through study completion (approximately 2 years)
|
To evaluate health-related Quality of Life (HR-QoL) in patients treated with olverembatinib plus chemotherapy.
|
Through study completion (approximately 2 years)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Elias Jabbour, M.D., M.D. Anderson Cancer Center
- Principal Investigator: Weili Zhao, M.D., Ph.D., Shanghai Jiaotong University School of Medicine Ruijin Hospital
- Principal Investigator: Suning Chen, M.D., Ph.D., First Affiliated Hospital of Suzhou Medical College
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Immune System Diseases
- Neoplasms by Histologic Type
- Hematologic Diseases
- Lymphatic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Leukemia, Lymphoid
- Leukemia
- Hemic and Lymphatic Diseases
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Tyrosine Kinase Inhibitors
- Antineoplastic Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- olverembatinib
Other Study ID Numbers
Other Study ID Numbers
- HQP1351AG301
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.